QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN N.V. (NYSE: QGEN) announced the formation of a Scientific Advisory Board to evaluate market and technology trends affecting its growth in Life Sciences and Molecular Diagnostics. The Board features industry leaders such as Dr. Peter Kaspar and Prof. Patrice Nordmann, chaired by Prof. Dr. Ross L. Levine. Additionally, QIAGEN will hold a virtual Annual General Meeting on June 29, 2021, addressing sustainability within an ESG framework and proposing re-elections for seven Supervisory Board members, alongside CEO Thierry Bernard and CFO Roland Sackers.
QIAGEN N.V. has received Emergency Use Authorization (EUA) from the FDA for its QIAreach® Anti-SARS-CoV-2 Total Test. This portable antibody testing device delivers results in about 10 minutes and can process up to 32 tests per hour using a digital eHub. The test has a sensitivity of 93.85% and a specificity of 97.83%. Developed with Ellume, this test aims to aid in monitoring immunity against COVID-19. QIAGEN also launched the QuantiFERON SARS-CoV-2 test for detecting T-cell responses. The new device enhances the efficiency of serological testing in healthcare settings.
QIAGEN N.V. (NYSE: QGEN) reported a 52% increase in net sales for Q1 2021, reaching $567.2 million. This surpassed the forecast of at least 45% growth. Adjusted earnings per share rose 94% to $0.66, exceeding the expected range of $0.60-0.62. The company's strong performance was attributed to a 16% growth in non-COVID product sales, making up 64% of total sales. QIAGEN also expanded its non-COVID portfolio and is positioned for sustainable growth beyond the pandemic.
QIAGEN N.V. (NYSE: QGEN) is set to launch the EZ2 Connect product line, an advanced automated sample-processing platform designed for biomedical research, forensics, and clinical diagnostics. Utilizing pre-filled cartridges and magnetic bead technology, it processes up to 24 samples in 20 minutes. The platform expands upon the successful EZ1 series, with applications in clinical diagnostics and forensics, and plans to introduce the EZ2 Connect MDx for molecular diagnostics in early 2022. The platform enhances lab automation, safety, and efficiency, backed by significant previous product installations.
QIAGEN and DiaSorin announced the launch of the LIAISON® LymeDetect® Assay, enhancing early detection of Lyme Borreliosis. This assay integrates antibody detection with a unique interferon-gamma release test, achieving a sensitivity of 74% within 21 days, significantly higher than the 49% of existing methods. With a specificity of 100%, it aims to address the critical diagnostic gap and may reduce healthcare costs through earlier treatment. The collaboration leverages both companies' strengths, with DiaSorin managing commercialization while they co-develop the product.
QIAGEN (NYSE: QGEN) has launched the artus® SARS-CoV-2 Prep&Amp UM Kit, enhancing COVID-19 testing efficiency through liquid-based sample preparation. This kit, now CE-IVD registered in the EU and under EUA review by the FDA, supports up to 672 samples in eight hours, reducing waste and time compared to standard methods. QIAGEN aims to increase testing capacity amidst ongoing COVID-19 cases, showcasing a versatile technology applicable beyond the pandemic. The company continues to expand its comprehensive SARS-CoV-2 testing solutions.
QIAGEN N.V. (NYSE: QGEN) announced its first quarter 2021 results will be released on May 3, 2021, at approximately 22:05 CET / 16:05 EDT. A conference call, hosted by CEO Thierry Bernard and CFO Roland Sackers, is scheduled for May 4, 2021, at 15:00 CET / 9:00 EDT. Interested parties can join via phone or access the webcast. The company is a leader in providing Sample to Insight solutions, serving over 500,000 customers globally in Molecular Diagnostics and Life Sciences. More details can be found through their contact at IR@qiagen.com.
QIAGEN N.V. (NYSE:QGEN) has launched the QIAseq DIRECT SARS-CoV-2 Kit, enhancing the efficiency of viral genome sequencing. This innovative kit reduces library preparation time to as little as four hours and decreases plastic use by 50%. It can multiplex up to 768 samples, improving throughput significantly. The kit is integrated with the QIAGEN Digital Insights CoV-2 Insights Service, designed for analyzing large viral datasets. This launch is a strategic expansion of QIAGEN’s portfolio, bolstering its position in the ongoing COVID-19 pandemic response.
QIAGEN N.V. (NYSE: QGEN) has received Emergency Use Authorization from the U.S. FDA for its NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay. This multiplex PCR test enables rapid identification and differentiation of respiratory viral infections, critical during the COVID-19 pandemic. With a processing time of 80 minutes, the test targets influenzas A and B, RSV, and SARS-CoV-2. The test, initially launched in the EU in 2020, enhances QIAGEN's diagnostics portfolio, supporting healthcare providers as respiratory infections increase.
QIAGEN N.V. (NYSE: QGEN) has filed its annual report for the year ending December 31, 2020, with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible via QIAGEN's website. The company specializes in Sample to Insight solutions, aiding over 500,000 global customers in molecular diagnostics and life sciences. As of the end of 2020, QIAGEN had over 5,600 employees in more than 35 locations worldwide. For further details, refer to their official site.